Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy

Annals of Surgical Oncology

Volumn 17, Issue 1, 2010, Pages 312-322

  Huang, Shu Pin ^a,b,c   Ting, Wen Chien ^d   Chen, Lu Min ^d   Huang, Li Chia ^d   Liu, Chia Chu ^a   Chen, Chien Wei ^e   Hsieh, Chi Jeng ^f,g   Yang, Wen Hui ^h   Chang, Ta Yuan ^h   Lee, Hong Zin ^h   Bao, Bo Ying ^h  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NOVARTIS PHARMA AG   (Switzerland)

^f ORIENTAL INSTITUTE OF TECHNOLOGY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; PROSTATE SPECIFIC ANTIGEN; WNT PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CASE CONTROL STUDY; COLON POLYPOSIS; CONTROLLED STUDY; GENE LOCATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HAPLOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; TUMOR SUPPRESSOR GENE;

ADENOMATOUS POLYPOSIS COLI PROTEIN; AGED; BETA CATENIN; CASE-CONTROL STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 74649083953     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0698-8     Document Type: Article

References (39)

1. M Han AW Partin CR Pound JI Epstein PC Walsh 2001 Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience Urol Clin North Am 28 555 565 10.1016/S0094-0143(05)70163-4 1:STN:280:DC%2BD3Mrktlaluw%3D%3D 11590814 (Pubitemid 32916759)
2. KA Roehl M Han CG Ramos JA Antenor WJ Catalona 2004 Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3, 478 consecutive patients: long-term results J Urol 172 910 914 10.1097/01.ju.0000134888.22332.bb 15310996 (Pubitemid 39096421)
3. PA Humphrey 2004 Gleason grading and prognostic factors in carcinoma of the prostate Mod Pathol. 17 292 306 10.1038/modpathol.3800054 14976540 (Pubitemid 41646608)
4. B Bierie M Nozawa JP Renou JM Shillingford F Morgan T Oka, et al. 2003 Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation Oncogene. 22 3875 3887 10.1038/sj.onc.1206426 1:CAS:528:DC%2BD3sXks1CnsLc%3D 12813461 (Pubitemid 36819661)
5. DR Chesire CM Ewing WR Gage WB Isaacs 2002 In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis Oncogene. 21 2679 2694 10.1038/sj.onc.1205352 1:CAS:528:DC%2BD38XjsVSmsr8%3D 11965541 (Pubitemid 34478326)
6. F Gounari S Signoretti R Bronson L Klein WR Sellers J Kum, et al. 2002 Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia Oncogene. 21 4099 4107 10.1038/sj.onc.1205562 1:CAS:528:DC%2BD38XltVymtb8%3D 12037666 (Pubitemid 34712877)
7. C Beroud T Soussi 1996 APC gene: database of germline and somatic mutations in human tumors and cell lines Nucleic Acids Res 24 121 124 10.1093/nar/24.1.121 1:CAS:528:DyaK28XnsV2qsg%3D%3D 8594558 (Pubitemid 26085747)
8. N Barker H Clevers 2006 Mining the Wnt pathway for cancer therapeutics Nat Rev Drug Discov. 5 997 1014 10.1038/nrd2154 1:CAS:528:DC%2BD28Xht1Kju7vK 17139285 (Pubitemid 44835127)
9. DR Chesire CM Ewing J Sauvageot GS Bova WB Isaacs 2000 Detection and analysis of beta-catenin mutations in prostate cancer Prostate. 45 323 334 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W 1:CAS:528:DC%2BD3cXovF2qs78%3D 11102958
10. AV Gerstein TA Almeida G Zhao E Chess M Shih Ie K Buhler, et al. 2002 APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers Genes Chromosomes Cancer. 34 9 16 10.1002/gcc.10037 1:CAS:528:DC%2BD38XjtFWjurc%3D 11921277 (Pubitemid 34260591)
11. HJ Voeller CI Truica EP Gelmann 1998 Beta-catenin mutations in human prostate cancer Cancer Res 58 2520 2523 1:CAS:528:DyaK1cXktVajt70%3D 9635571
12. JN Poynter KA Cooney JD Bonner KA White LP Tomsho G Rennert, et al. 2006 APC I1307K and the risk of prostate cancer Cancer Epidemiol Biomarkers Prev 15 468 473 10.1158/1055-9965.EPI-05-0584 1:CAS:528:DC%2BD28Xit1Oms7w%3D 16537703
13. SP Huang YH Chou WS Chang MT Wu CC Yu T Wu, et al. 2003 Androgen receptor gene polymorphism and prostate cancer in Taiwan J Formos Med Assoc 102 680 686 1:CAS:528:DC%2BD2cXitVyrsr0%3D 14691592
14. SP Huang YH Chou WS Wayne Chang MT Wu YY Chen CC Yu, et al. 2004 Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population Cancer Lett 207 69 77 10.1016/j.canlet.2003.12.006 1:CAS:528:DC%2BD2cXisF2gs7g%3D 15050735 (Pubitemid 38429888)
15. SP Huang CY Huang JS Wang CC Liu YS Pu HJ Yu, et al. 2007 Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy Clin Cancer Res. 13 6632 6638 10.1158/1078-0432.CCR-07-1437 1:CAS:528:DC%2BD2sXhtlSmu7nJ 18006764 (Pubitemid 350206798)
16. SP Huang CY Huang WJ Wu YS Pu J Chen YY Chen, et al. 2006 Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy Int J Cancer 119 1902 1907 10.1002/ijc.22053 1:CAS:528:DC%2BD28Xps1SnsLc%3D 16708371 (Pubitemid 44356849)
17. SP Huang WJ Wu WS Chang MT Wu YY Chen YJ Chen, et al. 2004 p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer Cancer Epidemiol Biomarkers Prev 13 2217 2224 1:CAS:528:DC%2BD2cXhtVOjsLnI 15598783
18. MJ Barry FJ Fowler Jr MP O'Leary RC Bruskewitz HL Holtgrewe WK Mebust, et al. 1992 The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association J Urol 148 1549 1557 1:STN:280:DyaK3s%2FlvFOksw%3D%3D 1279218 discussion 1564
19. DF Gleason GT Mellinger 1974 Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging J Urol 111 58 64 1:STN:280:DyaE2c7gt1Clug%3D%3D 4813554
20. SJ Freedland ME Sutter F Dorey WJ Aronson 2003 Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy Prostate-specific antigen. Urology. 61 365 369
21. KA Frazer DG Ballinger DR Cox DA Hinds LL Stuve RA Gibbs, et al. 2007 A second generation human haplotype map of over 3.1 million SNPs Nature 449 851 861 10.1038/nature06258 1:CAS:528:DC%2BD2sXhtFOjt7jL 17943122 (Pubitemid 47598626)
22. JC Barrett B Fry J Maller MJ Daly 2005 Haploview: analysis and visualization of LD and haplotype maps Bioinformatics. 21 263 265 10.1093/bioinformatics/bth457 1:CAS:528:DC%2BD2MXkt1WitQ%3D%3D 15297300 (Pubitemid 40202029)
23. SB Gabriel SF Schaffner H Nguyen JM Moore J Roy B Blumenstiel, et al. 2002 The structure of haplotype blocks in the human genome Science. 296 2225 2229 10.1126/science.1069424 1:CAS:528:DC%2BD38XkvFGhtrc%3D 12029063 (Pubitemid 34680308)
24. PI de Bakker R Yelensky I Pe'er SB Gabriel MJ Daly D Altshuler 2005 Efficiency and power in genetic association studies Nat Genet 37 1217 1223 10.1038/ng1669 16244653 (Pubitemid 41568704)
25. SS Li N Khalid C Carlson LP Zhao 2003 Estimating haplotype frequencies and standard errors for multiple single nucleotide polymorphisms Biostatistics. 4 513 522 10.1093/biostatistics/4.4.513 14557108
26. LP Zhao SS Li N Khalid 2003 A method for the assessment of disease associations with single-nucleotide polymorphism haplotypes and environmental variables in case-control studies Am J Hum Genet 72 1231 1250 10.1086/375140 1:CAS:528:DC%2BD3sXjslagurg%3D 12704570 (Pubitemid 36530010)
27. CI Truica S Byers EP Gelmann 2000 Beta-catenin affects androgen receptor transcriptional activity and ligand specificity Cancer Res 60 4709 4713 1:CAS:528:DC%2BD3cXmsFWiu7k%3D 10987273
28. SJ Freedland EB Humphreys LA Mangold M Eisenberger FJ Dorey PC Walsh, et al. 2005 Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA. 294 433 439 10.1001/jama.294.4.433 1:CAS:528:DC%2BD2MXms1ygsLk%3D 16046649 (Pubitemid 41124175)
29. SJ Freedland EB Humphreys LA Mangold M Eisenberger AW Partin 2006 Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality J Urol 176 1404 1408 10.1016/j.juro.2006.06. 017 16952644 (Pubitemid 44307204)
30. M Yeager N Orr RB Hayes KB Jacobs P Kraft S Wacholder, et al. 2007 Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 Nat Genet 39 645 649 10.1038/ng2022 1:CAS:528:DC%2BD2sXksFersb4%3D 17401363 (Pubitemid 46676108)
31. DG Bostwick HB Burke D Djakiew S Euling SM Ho J Landolph, et al. 2004 Human prostate cancer risk factors Cancer. 101 2371 2490 10.1002/cncr.20408 1:CAS:528:DC%2BD2cXhtVGmtbnF 15495199 (Pubitemid 39505434)
32. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics, 2007 CA Cancer J Clin. 57 43 66 10.3322/canjclin.57.1.43 17237035
33. YS Pu 2000 Prostate cancer in Taiwan: epidemiology and risk factors Int J Androl 23 Suppl 2 34 36 10.1046/j.1365-2605.2000.00012.x 10849490
34. P Wang M Dai W Xuan RC McEachin AU Jackson LJ Scott, et al. 2006 SNP Function Portal: a web database for exploring the function implication of SNP alleles Bioinformatics. 22 e523 529 10.1093/bioinformatics/btl241 1:CAS:528:DC%2BD28Xotl2rurs%3D 16873516 (Pubitemid 44288324)
35. P Berta JR Hawkins AH Sinclair A Taylor BL Griffiths PN Goodfellow, et al. 1990 Genetic evidence equating SRY and the testis-determining factor Nature. 348 448 450 10.1038/348448A0 1:CAS:528:DyaK3MXhvVOnsg%3D%3D 2247149
36. MH Werner JR Huth AM Gronenborn GM Clore 1995 Molecular basis of human 46X, Y sex reversal revealed from the three-dimensional solution structure of the human SRY-DNA complex Cell 81 705 714 10.1016/0092-8674(95)90532-4 1:CAS:528:DyaK2MXmtFOitbc%3D 7774012
37. RA Dubin H Ostrer 1994 Sry is a transcriptional activator Mol Endocrinol 8 1182 1192 10.1210/me.8.9.1182 1:STN:280:DyaK2M7ktVShsQ%3D%3D 7838151 (Pubitemid 24292595)
38. X Yuan ML Lu T Li SP Balk 2001 SRY interacts with and negatively regulates androgen receptor transcriptional activity J Biol Chem. 276 46647 46654 10.1074/jbc.M108404200 1:CAS:528:DC%2BD3MXptVyls78%3D 11585838
39. G Perinchery M Sasaki A Angan V Kumar P Carroll R Dahiya 2000 Deletion of Y-chromosome specific genes in human prostate cancer J Urol 163 1339 1342 10.1016/S0022-5347(05)67774-9 1:CAS:528:DC%2BD3cXisVSrurk%3D 10737540